Results 61 to 70 of about 10,135 (204)

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Assessment of the Myasthenia Gravis Patients’ Quality of Life

Pielęgniarstwo Neurologiczne i Neurochirurgiczne, 2023
Introduction. Myasthenia gravis is an immune-mediated disease associated with a disorder of the neuromuscular junction. MG belongs to the group of chronic diseases with variable clinical courses.
Weronika Jung-Plath, Marcelina Skrzypek-Czerko, Małgorzata Bilińska, Agata Zdun-Ryżewska   +3 more
doaj   +1 more source

Disfagia e Disartria. Forma Invulgar de Apresentação da Miastenia Gravis [PDF]

, 2007
Myasthenia Gravis is an autoimmune disorder that generally presents with ocular symptoms, specially diplopia and ptosis. Dysphagia may be a manifestation of the generalised type of the disease, but rarely is its presenting feature. The authors describe a
Alcântara, J, Claro, I, Ferreira, S, Lage, P, Nobre Leitão, C, Nunes, J   +5 more
core  

Facial expression recognition for emotion perception: A comprehensive science mapping

Ibrain, EarlyView.
Facial expression recognition (FER) has emerged as a pivotal interdisciplinary research domain, bridging computer science, psychology, neuroscience, and medicine. By mapping the FER scientific knowledge graph, the study aimed to explore the technological evolution and forecast future application trends in this field.
Hou‐Ming Kan, Li‐Ping Chen, Yu Zhang, Hao‐Yuan Hong, Ying‐Ying Qin, Yu‐Guo Cui, Yu‐Bo Mao, Yan‐Zhi Cheng, Zhe Lu, Hong‐Yan Ni, Xiao‐Tong Ding   +10 more
wiley   +1 more source

Anestesia peridural torácica para cirugía plástica de mama en paciente portadora de miastenia gravis: relato de caso [PDF]

, 2005
BACKGROUND AND OBJECTIVES: Myasthenia gravis is a chronic autoimmune disease characterized by skeletal muscles weakness promoted by decreased acetylcholine receptors in the neuromuscular junction.
Barbosa, Fabiano Timbó, Cavalcanti, Ismar Lima, Correia, Marta Cristiane Bezerra, Cunha, Rafael Martins Da   +3 more
core   +5 more sources

Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial

BJU International, Volume 135, Issue 4, Page 638-647, April 2025.
Objectives To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder. Patients and Methods This single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for ...
Meryam El Issaoui, Marlene Elmelund, Niels Klarskov   +2 more
wiley   +1 more source

The evaluation of approaches to the treatment of myasthenia gravis.

Medičnì Perspektivi, 2019
Myasthenia gravis is a relatively rare autoimmune disease with an undetermined aetiology which affects neuromuscular junctions. Currently, the following approaches to the treatment of myasthenia gravis are mainly distinguished: symptomatic treatment with
O. I. Kalbus, N. P. Shastun, S. O. Makarov, Yu. V. Bukreyeva, O. V. Somilo   +4 more
doaj   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

The fc fragment of IgMs binds C1q to activate the first step of the classical complement pathway, while inhibiting complement‐dependent cytotoxicity

The FEBS Journal, EarlyView.
Multimeric IgM‐fragment crystallizable region (Fc) fragments retain the ability to bind C1q and initiate the classical complement pathway, leading to C4 activation and deposition in vitro. However, the Fc cores can also inhibit complement‐dependent cytotoxicity by competing with surface‐bound antibodies for C1q engagement.
Andrea J. Pinto, Anne Chouquet, Isabelle Bally, Véronique Rossi, Nicole M. Thielens, Chantal Dumestre‐Pérard, Renate Kunert, Christine Gaboriaud, Wai Li Ling, Jean‐Baptiste Reiser   +9 more
wiley   +1 more source

Myasthenia gravis following the initiation of statin therapy: A multinational self‐controlled case series study

Journal of Internal Medicine, EarlyView.
Abstract Background Evidence regarding the risk of new‐onset myasthenia gravis (MG) following statin therapy initiation is limited. Objectives To investigate this potential adverse effect using multinational real‐world population‐based data. Methods A self‐controlled case series (SCCS) study was conducted using electronic medical records and claims ...
Vincent Ka Chun Yan, Wanchun Xu, Yuta Taniguchi, Kwun Kei Fung, Koon Ho Chan, Gary Kui Kai Lau, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Xue Li, Masao Iwagami, Rie Masuda, Nanako Tamiya, Sreemanee Raaj Dorajoo, Jing Wei Neo, Esther Wai Yin Chan, Ian Chi Kei Wong, Eric Yuk Fai Wan   +16 more
wiley   +1 more source